Oxford Immunotec to Present at the 2018 UBS Global Healthcare Conference


OXFORD, United Kingdom and MARLBOROUGH, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the 2018 UBS Global Healthcare Conference on Wednesday, May 23, 2018, at 9:30 a.m. ET.  The conference will be held at the Grand Hyatt Hotel in New York.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions.  The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.  Immunetics is a trademark of Immunetics, Inc.


For Media and Investor Inquiries: 
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Cargotec files listing application in respect of its bonds in the aggregate amount of EUR 250 million18.9.2019 13:00:00 CESTPress release

CARGOTEC CORPORATION, STOCK EXCHANGE RELEASE, 18 SEPTEMBER 2019 AT 2:00 PM (EEST) Cargotec files listing application in respect of its bonds in the aggregate amount of EUR 250 million NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Cargotec Plc decided on 13 September 2019 to issue two unsecured bonds in the total aggregate nominal amount of EUR 250 million. The first EUR 100 million bond matures on 23 January 2025 and carries a fixed annual interest of 1.250 per cent (ISIN: FI4000399688). The other, a EUR 150 million bond matures on 23 September 2026 and carries a fixed annual interest of 1.625 per cent (ISIN: FI4000399696). Cargotec Plc has today filed an application with Nasdaq Helsinki Ltd for the admission to trading of the bonds on the official list of Nasdaq Helsinki Ltd. Such application is subject to the F

New liquidity providing agreement for Aspo Plc’s share18.9.2019 12:00:00 CESTPress release

ASPO Plc Stock exchange release September 18, 2019 at 13:00 New liquidity providing agreement for Aspo Plc’s share Aspo Plc and Lago Kapital Ltd have signed a market making agreement in compliance with the Liquidity Providing (LP) requirements issued by Nasdaq Helsinki Ltd. Concurrently, Aspo has terminated its current liquidity providing agreement with Nordea Bank. The current agreement will be in force until Friday October 18, 2019. The new liquidity providing agreement will commence on Monday 21 October, 2019. According to the agreement, Lago Kapital Ltd will provide Aspo’s share with bids and offers so that the maximum spread is 3 per cent, calculated from the bid quotation. Both bid and offer side shall include a number of shares corresponding to the value of at least 3,000 euros. The agreement is in force for a fixed period of 3 months and thereafter until terminated with one month’s term of notice. The market making agreement aims at increasing the share's liquidity and decreasi

Suominen’s financial reporting in 202018.9.2019 12:00:00 CESTPress release

Suominen Corporation's stock exchange release on September 18, 2019 at 1:00 p.m. EEST Suominen will publish its Financial Statements Release, Half Year Financial Report and two Interim Reports in 2020 as follows: January 29, 2020 - Financial Statements Release for 2019 April 23, 2020 - Interim Report for January-March 2020 August 12, 2020 - Half Year Financial Report for January-June 2020 October 22, 2020 - Interim Report for January-September 2020 The Annual Report for 2019 will be published during the week starting on February 24, 2020 (week 9) at the latest. Suominen's Annual General Meeting is planned to be held on Thursday, March 19, 2020. Suominen's Board of Directors will summon the meeting at a later date. For more information: Emilia Peltola, VP, Communications and IR, tel. +358 10 214 3082 Suominen manufactures nonwovens as roll goods for wipes as well as for medical and hygiene products. The end products made of Suominen’s nonwovens – wet wipes, feminine care products and sw

Nomination Committee for SEB appointed18.9.2019 10:00:00 CESTPress release

Press release Stockholm 18 September 2019 Nomination Committee for SEB appointed SEB’s Annual General Meeting will be held on Monday, 23 March 2020. The Nomination Committee members are: Petra Hedengran, Investor, Chairman Magnus Billing, Alecta Lars Heikensten, Trygg-Stiftelsen Johan Sidenmark, AMF Marcus Wallenberg, Chairman of the Board, SEB The shareholders having appointed members of the Nomination Committee together represent approximately 36,1 per cent of the voting rights for all shares in the Bank. The SEB Board has appointed Sven Nyman additional member of the Committee. The Nomination Committee will prepare a proposal for Directors etc. to be presented to the Annual General Meeting 2020 for decision. The matters to be dealt with by the Nomination Committee are described on under the heading ‘Annual General Meeting’. A shareholder who would like to submit a proposal to the Nomination Committee can do so by e-mail to or by ordinary

Valberedning för SEB utsedd18.9.2019 10:00:00 CESTPressemelding

Pressmeddelande Stockholm 18 september 2019 Valberedning för SEB utsedd Årsstämma för Skandinaviska Enskilda Banken kommer att hållas måndagen den 23 mars 2020. Valberedningen består av: Petra Hedengran, Investor, ordförande Magnus Billing, Alecta Lars Heikensten, Trygg-Stiftelsen Johan Sidenmark, AMF Marcus Wallenberg, styrelsens ordförande, SEB De aktieägare som utsett ledamöter till valberedningen, representerar tillsammans cirka 36,1 procent av röstetalet för samtliga aktier i banken. SEB:s styrelse har utsett Sven Nyman att vara adjungerad ledamot av valberedningen. Valberedningen har till uppgift att arbeta fram ett förslag till styrelse m.m. att läggas fram för beslut på årsstämman 2020. De frågor valberedningen ska behandla finns beskrivna på under rubriken ”Årsstämma”. Aktieägare som önskar lämna förslag till valberedningen kan göra det med e-post till eller med brev till Skandinaviska Enskilda Banken AB, Valberedningen, Att: Ulf Thornan

MiniMed™ 670G System European Real-World Data Shows 73% Time in Range, Beyond Recommended Targets18.9.2019 09:00:00 CESTPress release

DUBLIN, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions today announced real-world clinical outcomes on European patients for the MiniMed™ 670G system. The European data showed an average Time in Range of 73%1, a result that exceeds the recommended Time in Range consensus guidelines of 70% that were recently published2. The real-world data of 4,369 patients showed an average estimated HbA1c of 6.9%*1, also surpasses the recommended target.3 The SmartGuard™ Auto Mode feature in the MiniMed 670G system automates and personalizes the delivery of basal insulin 24 hours a day. This system is the only commercially available technology in the world to provide protection from highs and lows, and proactively drive increased Time in Range by consistently guiding to the target of 120 mg/dL (6.7mmol/L) throughout the day.4,5 “The Time in Range clinical guidelines recommend that the target of effective diabetes management